CD80 and myeloid sarcoma: B cells from MS patients exhibit higher surface expression of HLA-DR, CD40, and CD80/86 than healthy donor (HC) derived B cells suggesting that B cells may be highly poised towards antigen presentation in the MS patients (4) with CD40, CD80, and CD86, also contributing towards significant genetic risk (5).